Skip to search formSkip to main contentSkip to account menu

10 ML nivolumab 10 MG/ML Injection [Opdivo]

Known as: NIVOLUMAB 10 mg in 1 mL INTRAVENOUS INJECTION [OPDIVO], Opdivo 100 MG in 10 ML Injection, Opdivo 100 MG per 10 ML Injection 
National Institutes of Health

Related topics

Related topics

10 relations
Hydrochloric AcidInjectionMannitolPentetic Acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Nivolumab vs investigator ’ s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck : Efficacy and safety in CheckMate 141 by prior cetuximab use
  • 2019
  • Corpus ID: 157059814
104 Clinical Science Symposium: "Check" This Out: The Step Beyond PD-1 Blockade Sunday, June 4, 10:12–10:24 AM, Hall D1 Clinical… 
2018
2018
[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
2017
2017
First Patient Dosed in a Phase 1 / 2 Trial of Pexa-Vec + Opdivo ® for the First-Line Treatment of Advanced Liver Cancer
  • 2017
  • Corpus ID: 166220677
Strasbourg, France, July 31, 2017, 5:45 p.m. CET Transgene (Euronext Paris: TNG), a company that designs and develops viral-based… 
2017
2017
Measuring Markers of Immune Response in Patients Treated with Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®)
Highly Cited
2017
Highly Cited
2017
Anti‐PD1‐induced psoriasis: a study of 21 patients
Nivolumab (Opdivo®), pembrolizumab (Keytruda®), atezolizumab, and pidilizumabab are anti-PD1 monoclonal antibodies. Nivolumab is… 
2016
2016
Companion and complementary diagnostics for PD-L1 expression assessment in non-small cell lung cancer.
11612Background: Recently two different immunohistochemical assays for PD-L1 expression in non-small cell lung cancers have been… 
Review
2016
Review
2016
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK… 
2016
2016
Immunothérapie des cancers : rationnel et avancées récentes
Review
2015
Review
2015
Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
Nivolumab (Opdivo®; Nivolumab BMS™) was the first programmed death (PD)-1 immune checkpoint inhibitor to be approved for use in… 
Review
2014
Review
2014
Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
Nivolumab (Opdivo®) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)